Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.74 |
| ▸ | PGR | P06401 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | CNR1 | P21554 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | SHBG | P04278 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349803 | 0.90 | ESR1 (0.78) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL17326003 | 0.90 | ESR1 (0.78) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL17318121 | 0.89 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL19123270 | 0.89 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL4395173 | 0.89 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL6872679 | 0.89 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL19096138 | 0.89 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL8505089 | 0.88 | ESR1 (0.81) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL4389365 | 0.87 | ESR1 (0.77) | ESR1LMNANR3C1PGRCYP3A4 | |
| SCHEMBL8931573 | 0.87 | ESR1 (0.74) | ESR1LMNANR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761252-A1 | MATRIX-CONTROLLED TRANSDERMAL THERAPEUTIC SYSTEM BASED ON AN ADHESIVE FOR ADMINISTERING NORELGESTROMIN OR THE COMBINATION THEREOF WITH AN ESTROGEN | HEXAL AG (DE) | 2007-03-14 | — | — | EP | claimed |
| WO-2005120470-A1 | MATRIX-CONTROLLED TRANSDERMAL THERAPEUTIC SYSTEM BASED ON AN ADHESIVE FOR ADMINISTERING NORELGESTROMIN OR THE COMBINATION THEREOF WITH AN ESTROGEN | HEXAL AG (DE) | 2005-12-22 | — | — | WO | claimed |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-4484429-A1 | COMPOUND AND USE THEREOF | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20200222352-A1 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS | QURETINO THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20180133189-A1 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS | QURETINO THERAPEUTICS, INC. | 2018-05-17 | — | — | US | disclosed |
| EP-2613772-B1 | LOW-DOSE TRANSDERMAL PATCHES WITH HIGH DRUG RELEASE | BAYER IP GMBH (DE) | 2016-12-14 | — | — | EP | disclosed |
| US-20160038451-A1 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS | QURETINO THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| EP-1054675-A1 | REGULATION OF ESTRUS AND OVULATION IN GILTS | Thorn Bioscience, LLC (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6028057-A | INDUCING PSEUDOPREGNANCY IN FERTILE FEMALE PIGS COMPRISING ADMINISTERING TO THE PIGS AN EFFECTIVE AMOUNT OF A COMPOUND THAT INDUCES PSEUDOPREGNANCY IN A BIODEGRADABLE CONTROLLED RELEASE FORMULATION | THORN BIOSCIENCE, LLC (US) | 2000-02-22 | — | — | US | disclosed |
| US-6013276-A | TREATING MENOPAUSE OR OSTEOPOROSIS USING A TRANSDERMAL MATRIX SYSTEM CONTAINING ETHYLENE-VINYL ACETATE COPOLYMER, 2-OCTADODECYL MYRISTATE, N(C4-C15)ALKYL-2-PYRROLIDONES AND ATLEAST ONE HORMONE SELECTED FROM PROGESTIN AND ESTROGEN | LABORATORIES D'HYGIENE ET DE DIETETIQUE (FR) | 2000-01-11 | — | — | US | disclosed |
| WO-1999042110-A1 | REGULATION OF ESTRUS AND OVULATION IN GILTS | THORN BIOSCIENCE, LLC (US) | 1999-08-26 | — | — | WO | disclosed |
| US-5605702-A | Eva-based transdermal matrix system for the administration of an estrogen and/or a progestogen | LABORATOIRES D'HYGIENE ET DE DIETETIQUE (FR) | 1997-02-25 | — | — | US | disclosed |
| US-5580572-A | FOR PERCUTANEOUS ADMINISTRATION OF HORMONES | LABORATOIRES D'HYGIENE ET DE DIETETIQUE (FR) | 1996-12-03 | — | — | US | disclosed |
| US-5128124-A | Administration of norethistereone-17-acetate | CIBA-GEIGY CORPORATION (US) | 1992-07-07 | — | — | US | disclosed |
| US-4913905-A | PATCH CONTAINING ESTROGEN, SYNTHETIC GESTAGEN, ALKANOL TO ENHANCE PERCUTANEOUS ABSORPTION | CIBA-GEIGY CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
| EP-0285563-A1 | Transdermal therapeutic systems for combinations of active agents | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133189-A1 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS | RARA, RARB, RARG | ESR1 254/4885LMNA 1683/4885NR3C1 281/4885 |
| US-20200222352-A1 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS | RARA, RARB, RARG | ESR1 254/4885LMNA 1683/4885NR3C1 281/4885 |
| US-20160038451-A1 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS | RARA, RARB, RARG | ESR1 254/4885LMNA 1683/4885NR3C1 281/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | ESR1 3467/4885LMNA 2675/4885NR3C1 921/4885 |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | CYP17A1, CYP11B2, CYP21A2 | ESR1 3792/4885LMNA 1711/4885NR3C1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.